Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: Xolair

First Posted Date: 2020-12-02

Last Posted Date: 2023-08-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT04648930

Locations: 🇯🇵
Novartis Investigative Site, Saitama, Japan

Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

Active, not recruiting

Conditions: Lupus Nephritis

Interventions: Drug: Myfortic

First Posted Date: 2020-11-27

Last Posted Date: 2024-12-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT04645589

Locations: 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Phase 2

Active, not recruiting

Conditions: NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

Interventions: Biological: Placebo
Biological: MAS825

First Posted Date: 2020-11-23

Last Posted Date: 2024-11-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT04641442

Locations: 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸
Children´s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Texas Children´s Hospital, Houston, Texas, United States

and more 7 locations

Secukinumab Open Label Roll-over Extension Protocol

Phase 4

Recruiting

Conditions: Autoimmunity, Inflammation

Interventions: Biological: Secukinumab s.c. injection

First Posted Date: 2020-11-20

Last Posted Date: 2024-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 715

Registration Number: NCT04638647

Locations: 🇺🇸
Austin Regional Clinic Rheumatology, Austin, Texas, United States
🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸
Purushotham Akther and Roshan Kotha MD Inc, La Mesa, California, United States

and more 25 locations

Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)

Phase 3

Withdrawn

Conditions: Post Myocardial Infarction

Interventions: Drug: sacubitril/valsartan

First Posted Date: 2020-11-19

Last Posted Date: 2021-11-26

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04637555

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Phase 1

Completed

Conditions: Macular Edema
Neovascular Age-related Macular Degeneration
Diabetic Macular Edema
Retinal Vein Occlusion

Interventions: Drug: MHU650

First Posted Date: 2020-11-19

Last Posted Date: 2023-05-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 21

Registration Number: NCT04635800

Locations: 🇵🇷
Novartis Investigative Site, Arecibo, Puerto Rico

Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Biological: Secukinumab
Biological: Ustekinumab

First Posted Date: 2020-11-17

Last Posted Date: 2024-12-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 119

Registration Number: NCT04632927

Locations: 🇩🇪
Novartis Investigative Site, Ratingen, Germany

A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: Beovu

First Posted Date: 2020-11-17

Last Posted Date: 2023-11-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 329

Registration Number: NCT04632056

Locations: 🇯🇵
Novartis Investigative Site, Osaka, Japan

Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)

Phase 2

Completed

Conditions: Chronic Ocular Pain

Interventions: Drug: SAF312
Other: SAF312 Placebo

First Posted Date: 2020-11-16

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 153

Registration Number: NCT04630158

Locations: 🇺🇸
NVISION Eye Centers, Newport Beach, California, United States
🇺🇸
Periman Eye Institute, Seattle, Washington, United States
🇺🇸
Gordon Schanzlin New Vision Inst, San Diego, California, United States

and more 15 locations

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Biological: Sabatolimab
Drug: Azacitidine

First Posted Date: 2020-11-10

Last Posted Date: 2024-11-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT04623216

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy